UT System hosts technology transfer show
UTMB’s Carney, Gorenstein among inaugural award recipients
APRIL 2, 2007--The University of Texas System recently hosted its inaugural Research and Technology Transfer Showcase to highlight the research capabilities, discoveries, inventions and new ventures of its component institutions.
Two UTMB faculty members—Dr. Darrell Carney, professor of biochemistry and molecular biology, and Dr. David Gorenstein, associate dean of research—were honored during the Chancellor’s Entrepreneurship and Innovation Awards.
Chancellor Mark Yudof recognized Carney for his work on the development and commercialization of thrombin-derived peptide, Chrysalin (TP508). Gorenstein was honored for his efforts in creating the Gulf Coast Consortium for Structural Biology—a group of leading biomedical research institutions in the Houston-Galveston area.
The event showcased the most recent internationally recognized research, discoveries and commercial developments at the UT System. This successful event was brought about by the enthusiastic participation of the technology transfer and research translation teams from the nine academic and six health institutions of the UT System. Dr. James Arie and his team from the Center for Technology Development at UTMB were on hand at the event to discuss UTMB’s strides in biomedical research, its accomplishments in technology commercialization and to present the research development opportunities on Galveston Island. Other participants included angel investors, venture capitalists, entrepreneurs and several legislative staff members.
Texas State Comptroller Susan Combs and UT System Chancellor Mark G. Yudof delivered the keynote addresses and emphasized the importance of research and innovation to the success of the UT System and the economic development of the state of Texas.
For decades, UT System institutions and their scientists have been pioneers of cutting-edge technology, and in fiscal year 2006 they generated more than $1.8 billion for research, helping create 14 start-up companies and accounting for 117 U.S. patents that year.